Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

CORE Kidney ... from baseline to week 12. Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

Eli Lilly, after tirzepatide's late-stage cardio win ... blood clotting, liver cancer, kidney disease, bacterial infections, pneumonia and Parkinson’s disease, according to the researchers.

Now they are being found to treat cardiovascular and kidney disease ... for diabetes and Wegovy for weight loss, and Eli Lilly, which makes tirzepatide, a more effective alternative, have together ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study ...

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...

CORE Kidney, a patient support and ... over 176 weeks. Tirzepatide demonstrated sustained average weight loss of Eli Lilly and Company (NYSE: LLY) today announced that data from studies of ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

Eli Lilly & Co. LLY is a major global pharmaceutical company in the medical sector. The company made headlines with its dominant GLP-1 drug, Tirzepatide, sold as Mounjaro for type 2 diabetes and ...